Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Acelyrin Inc (SLRN)

Acelyrin Inc (SLRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Alumis Stockholders Approve Merger with ACELYRIN GlobeNewswire - Tue May 13, 2025

SLRN : 2.27 (+1.79%)
ALMS : 26.80 (+4.56%)
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases GlobeNewswire - Tue May 13, 2025

SLRN : 2.27 (+1.79%)
ALMS : 26.80 (+4.56%)
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis GlobeNewswire - Tue May 6, 2025

SLRN : 2.27 (+1.79%)
ALMS : 26.80 (+4.56%)
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis GlobeNewswire - Thu May 1, 2025

SLRN : 2.27 (+1.79%)
ALMS : 26.80 (+4.56%)
Alumis and ACELYRIN Announce Amended Merger Agreement GlobeNewswire - Mon Apr 21, 2025

SLRN : 2.27 (+1.79%)
ALMS : 26.80 (+4.56%)
Alumis and ACELYRIN Announce Amended Merger Agreement GlobeNewswire - Mon Apr 21, 2025

SLRN : 2.27 (+1.79%)
ALMS : 26.80 (+4.56%)
3 Biopharmaceutical Stocks Bucking the Sell-Off MarketBeat - Thu Apr 10, 2025

Three biopharma companies may appeal to investors looking for firms that have not been rocked by tariff-inspired turbulence.

CORT : 38.34 (-6.10%)
DBVT : 21.69 (-4.03%)
SLRN : 2.27 (+1.79%)
ABBV : 227.50 (+2.99%)
ALMS : 26.80 (+4.56%)
Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger GlobeNewswire - Fri Apr 4, 2025

SLRN : 2.27 (+1.79%)
ALMS : 26.80 (+4.56%)
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan GlobeNewswire - Thu Mar 13, 2025

SLRN : 2.27 (+1.79%)
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger GlobeNewswire - Tue Mar 4, 2025

SLRN : 2.27 (+1.79%)

Barchart Exclusives

1 High-Yield Dividend Stock to Buy Hand Over Fist in February 2026 Barchart - 57 minutes ago
TotalEnergies screens as a “buy hand over fist” dividend play because it couples a roughly 5% yield and sub‑12× forward P/E with resilient oil and gas cash flows and long-dated PPAs like the 1‑GW Google Texas solar deal. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot